You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
猴痘概念股集體走強 之江生物和蘭衞醫學漲超11% 我國開啟入境人員猴痘排查
格隆匯 07-04 11:25
格隆匯7月4日丨之江生物漲近15%,蘭衞醫學漲超11%,江蘇吳中、阿拉丁、華仁藥業漲超8%,普利製藥漲7%,東方生物、熱景生物、翰宇藥業、一品紅漲超6%,碩世生物、安旭生物、萬孚生物、康辰藥業漲超5%。美國專家稱猴痘疫情在美國有失控風險;中國國家衞健委發佈《猴痘防控技術指南(2022年版)》指出,各地應主動對入境人員進行猴痘病毒排查。衞健委指出,接種天花疫苗可預防猴痘,我國既往的天花疫苗為複製型組織培養痘苗,暴露前接種可有效保護人羣免受感染,而暴露後2周內,尤其是最初4天內接種者,約85%可產生免疫力,減輕症狀嚴重性。2019年美國批准了一款可用於職業暴露風險人羣的非複製型猴痘疫苗Jynneos(MVA-BN),國內非複製型痘苗正在研發中。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account